NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Friday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets lowered their price objective on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Up 1.7 %

NYSE NBY opened at $0.58 on Friday. The company has a market capitalization of $2.83 million, a price-to-earnings ratio of -0.01 and a beta of 0.69. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $9.08. The stock has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.97.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.